Fundz

Ventuno Biotech Secures €3m Seed Round to Power Next-Gen Cancer Immunotherapies, Led by Octalfa.

PRIVATENov 27, 2025

Amount Raised

€3 Million

Round Type

Seed

LyonBiotechnologyHealth Care

Investors

BNP Paribas InnovationCaisse D'epargne Rhône AlpesArmand BensussanGilles AlbericiOctalfaRelyens Innovation SantéTurenne Santé

Description

Ventuno Biotech has successfully closed a €3m seed round financing to support its innovative cancer immunotherapies. The round includes €2m in equity led by Octalfa and €1m in loans from major banking partners. This funding will enhance their discovery and translational research programs. The financing demonstrates strong investor confidence in Ventuno's approach to tackling resistant cancers.

Who else raised in Biotechnology and Health Care around the same time

Companies in the same sectors as Ventuno Biotech that raised within 45 days of this round, from Fundz verified event records.

  • Aurora Therapeutics raised $16M (Seed) on January 9, 2026.
  • AirNexis Therapeutics raised $62M on January 9, 2026.
  • Find Therapeutics raised $7.9M (Series A) on January 9, 2026.
  • Ventaris Surgical raised $30M (Series A) on January 9, 2026.
  • Diagonal Therapeutics raised $125M (Series B) on January 8, 2026.
  • Parabilis Medicines raised $305M (Series F) on January 8, 2026.

Who to call at Ventuno Biotech, and when

A new round usually means Ventuno Biotech is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Ventuno Biotech raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Ventuno Biotech, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Ventuno Biotech. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Ventuno Biotech

Location

Lyon, Auvergne Rhône Alpes, France

About

Ventuno Biotech is a start-up focused on developing next-generation cancer immunotherapies. Founded in February 2025, the company aims to create novel therapeutic strategies to stimulate anti-cancer immunity. It has a solid scientific and business plan shaped during two years of incubation at Octalfa. The company is committed to accelerating the development of its lead immuno-oncology assets.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Ventuno Biotech raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

2 contacts
Verified contactsJeremy B., CEO hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Ventuno Biotech's next move

See what Strategic adds

Ventuno Biotech raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.